Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Aims: Upper tract urothelial carcinoma (UTUC) is a rare malignancy with a poor prognosis which occurs sporadically or in few cases results from a genetic disorder called Lynch syndrome. Recently, examination of microsatellite instability (MSI) has gained importance as a biomarker: MSI tumours are associated with a better response to immunomodulative therapies. Limited data are known about the prevalence of MSI in UTUC. New detection methods using the fully automated Idylla MSI Assay facilitate analysis of increased patient numbers. Methods: We investigated the frequency of MSI in a multi-institutional cohort of 243 consecutively collected UTUC samples using standard methodology (Bethesda panel), along with immunohistochemistry of mismatch repair (MMR) proteins. The same tumour cohort was retested using the Idylla MSI Assay by Biocartis. Results: Using standard methodology, 230/243 tumours were detected as microsatellite stable (MSS), 4/243 tumours as MSI and 9/243 samples as invalid. In comparison, the Idylla MSI Assay identified four additional tumours as MSS, equalling 234/243 tumours; 4/243 were classified as MSI and only 5/243 cases as invalid. At the immunohistochemical level, MSI results were supported in all available cases with a loss in MMR proteins. The overall concordance between the standard and the Idylla MSI Assay was 98.35%. Time to result differed between 3 hours for Idylla MSI Assay and 2 days with the standard methodology. Conclusion: Our data indicate a low incidence rate of MSI tumours in patients with UTUC. Furthermore, our findings highlight that Idylla MSI Assay can be applied as an alternative method of MSI analysis for UTUC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Deficiencies in MMR are detected using a consensus marker panel (Bethesda panel) and immunohistochemistry (IHC), although a more rapid PCR method using seven markers of MSI (Idylla MSI assay) appears promising [130].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [130]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087
Microsatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022289 · Cited by 2,160
Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M., & Reuter, V. E. (2016) · European Urology · doi:10.1016/j.eururo.2016.02.028 · Cited by 1,916
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update
Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R. J., Burger, M., Cowan, N. C., Gontero, P., Van Rhijn, B. W. G., Mostafid, A. H., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.07.036 · Cited by 1,514
Rouprêt, M., Babjuk, M., Compérat, E., Zigeuner, R., Sylvester, R. J., Burger, M., Cowan, N. C., Böhle, A., Van Rhijn, B. W. G., Kaasinen, E., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.06.044 · Cited by 1,341
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176 · cited 1×
“9 14 Currently, detection of MSI is mostly performed using the National Cancer Institute (NCI) consensus marker panel accompanied by immunohistochemistry analysis, which results in a time- to-diagnosis period of approximately two working days.”
Luchini, C., Bibeau, F., Ligtenberg, M. J. L., Singh, N., Nottegar, A., Bosse, T., Miller, R., Riaz, N., Douillard, J.-Y., Andre, F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz116 · Cited by 1,041
Dietmaier, W., Wallinger, S., Bocker, T., Kullmann, F., Fishel, R. A., & Rüschoff, J. (1997) · PubMed · Cited by 742
Self-citationColin, P., Koenig, P., Ouzzane, A., Berthon, N., Villers, A., Biserte, J., & Rouprêt, M. (2009) · BJU International · doi:10.1111/j.1464-410x.2009.08838.x · Cited by 300
Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma
Shariat, S. F., Favaretto, R. L., Gupta, A., Fritsche, H.-M., Matsumoto, K., Kassouf, W., Walton, T. J., Tritschler, S., Baba, S., Matsushita, K., et al. (2011) · World Journal of Urology · doi:10.1007/s00345-010-0594-7 · Cited by 185
Evrard, C., Tachon, G., Randrian, V., Karayan-Tapon, L., & Tougeron, D. (2019) · Cancers · doi:10.3390/cancers11101567 · Cited by 181
Distinct patterns of microsatellite instability are seen in tumours of the urinary tract
Catto, J. W. F., Azzouzi, A.-R., Amira, N., Rehman, I., Feeley, K. M., Cross, S. S., Fromont, G., Sibony, M., Hamdy, F. C., Cussenot, O., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206964 · Cited by 144
Frequent microsatellite instability in sporadic tumors of the upper urinary tract.
Hartmann, A., Zanardo, L., Edmonston, T. B., Blaszyk, H., Dietmaier, W., Stoehr, R., Cheville, J. C., Junker, K., Wieland, W. F., Knuechel, R., et al. (2002) · PubMed · Cited by 129
Self-citationMorgan Rouprêt, A., Fromont, G., Azzouzi, A.-R., Catto, J. W., Vallancien, G., Hamdy, F. C., & Cussenot, O. (2005) · Urology · doi:10.1016/j.urology.2005.01.019 · Cited by 88
Zhao, H., Thienpont, B., Yesilyurt, B. T., Moisse, M., Reumers, J., Coenegrachts, L., Sagaert, X., Schrauwen, S., Smeets, D., Matthijs, G., et al. (2014) · eLife · doi:10.7554/elife.02725 · Cited by 85 · cited 1×
“16 In previous reports, the new marker set has previously been approved by in vitro diagnostic regulation including Conformité Européenne (CE) marking as an alternative testing method for MSI analysis in colorectal carcinoma.”
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W. W., Cushman‐Vokoun, A. M., Funkhouser, W. K., Kopetz, S., Lieu, C. H., Lindor, N. M., Minsky, B. D., et al. (2017) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw209 · Cited by 68
Chapusot, C., Martin, L., Bouvier, A., Bonithon‐Kopp, C., Laubriet, A., Rageot, D., Ponnelle, T., Laurent‐Puig, P., Faivre, J., & Piard, F. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600474 · Cited by 63 · cited 1×
“33 Lastly, the isolated loss of the MSH6 protein with MSS status in two tumours could indicate a different way of activation among the MMR pathways.”
Burger, M., Denzinger, S., Hammerschmied, C. G., Tannapfel, A., Obermann, E. C., Wieland, W. F., Hartmann, A., & Stoehr, R. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0074-0 · Cited by 58
Self-citationEricson, K., Isinger-Ekstrand, A., Isfoss, B. L., & Nilbert, M. C. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-23 · Cited by 52 · cited 1×
“30 31 Importantly, patient median age appears not to be a factor explaining the MSI differences since among the aforementioned studies patients had a median age from 65 to 71 years.”
Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma
Li, Q., Bagrodia, A., Cha, E. K., & Coleman, J. (2016) · Current Urology Reports · doi:10.1007/s11934-015-0566-y · Cited by 43 · cited 1×
“25 26 In this study, we evaluated the”
Molecular aspects of upper tract urothelial carcinoma
Patel, N. S., Arya, M., Muneer, A., Powles, T., Sullivan, M., Hines, J. E. W., & Kelly, J. D. (2013) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.10.002 · Cited by 41
Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma
Arabi, H., Guan, H., Kumar, S., Coté, M. L., Bandyopadhyay, S., Bryant, C. S., Shah, J. P., Abdul‐Karim, F. W., Munkarah, A. R., & Ali‐Fehmi, R. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.02.004 · Cited by 38
Molecular subtype classification of urothelial carcinoma in Lynch syndrome
Therkildsen, C., Eriksson, P., Höglund, M., Jönsson, M., Sjödahl, G., Nilbert, M. C., & Liedberg, F. (2018) · Molecular Oncology · doi:10.1002/1878-0261.12325 · Cited by 38
Nardon, E., Glavač, D., Benhattar, J., Groenen, P. J. T. A., Höfler, G., Höfler, H., Jung, A., Keller, G., Kirchner, T., Lessi, F., et al. (2010) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e3181db67af · Cited by 35
Schneider, B., Glass, A. S., Jagdmann, S., Hühns, M., Claus, J., Zettl, H., Dräger, D. L., Maruschke, M., Hakenberg, O. W., Erbersdobler, A., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2020.03.006 · Cited by 29 · cited 2×
“7 8 27–29 For example, Hartmann et al analysed 62 UTUC samples and identified a frequency of 21% MSI.”
InfluentialUniversal Mismatch Repair Protein Screening in Upper Tract Urothelial Carcinoma
Gayhart, M. G., Johnson, N., Paul, A. K. R., Quillin, J. M., Hampton, L. J., Idowu, M. O., & Smith, S. C. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqaa100 · Cited by 25 · cited 1×
“28 Nonetheless, there are a few studies describing a discordance between MSI analysis and immunohistochemistry in colorectal cancer, where in some cases an isolated MSH6 loss is associated with an MSS status.”
Fadhil, W., & Ilyas, M. (2012) · Histopathology · doi:10.1111/j.1365-2559.2011.04021.x · Cited by 24
Giedl, J., Schneckenpointner, R., Filbeck, T., Ruemmele, P., Hofstaedter, F., Burger, M., Hartmann, A., & Stoehr, R. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpvtcj4vu5hkvz · Cited by 23
Self-citationLi, X., Xu, J., Li, L., Mu, X., Wang, Y., & Li, X. (2019) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.05.006 · Cited by 17 · cited 1×
“32 In our study of 243 UTUCs, we observed a high concordance of 98.35% of MSI testing between the two methods.”
InfluentialCraene, B. D., de Velde, J. V., Rondelez, E., Vandenbroeck, L., Peeters, K., Vanhoey, T., Elsen, N., Vandercruyssen, G., Melchior, L. C., Willemoe, G. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15639 · Cited by 16
Necchi, A., Pal, S. K., Ross, J. S., Madison, R. W., Agarwal, N., Sonpavde, G., Joshi, M., Yin, M., Miller, V. A., Grivas, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.4581 · Cited by 7 · cited 2×
“30 31 Importantly, patient median age appears not to be a factor explaining the MSI differences since among the aforementioned studies patients had a median age from 65 to 71 years.”
Zhao, H., Craene, B. D., Sagaert, X., Amant, F. C., Maertens, G. G., & Lambrechts, D. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.e15654 · Cited by 2
Cited by
Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“Deficiencies in MMR are detected using a consensus marker panel (Bethesda panel) and immunohistochemistry (IHC), although a more rapid PCR method using seven markers of MSI (Idylla MSI assay) appears promising [130].”
MethodKavun, A., Veselovsky, E., Lebedeva, A., Belova, E., Kuznetsova, O. A., Yakushina, V. D., Grigoreva, T. V., Mileyko, V., Fedyanin, M. Y., & Ivanov, M. V. (2023) · Cancers · doi:10.3390/cancers15082288 · Cited by 61
Chandran, E. B. A., Iannantuono, G. M., Atiq, S. O., Akbulut, D., Sinaii, N., Simon, N. I., Banday, A. R., Boudjadi, S., Gurram, S., Nassar, A. H., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000335 · Cited by 38
Rasmussen, M., Madsen, M. G., & Therkildsen, C. (2022) · Urology · doi:10.1016/j.urology.2022.02.006 · Cited by 22
Upper tract urothelial carcinoma: epidemiology, presentation, and high-risk endemic populations
Clark, C. B., Matheny, M. V., & Raman, J. D. (2024) · Current Opinion in Urology · doi:10.1097/mou.0000000000001242 · Cited by 13
Metadata
- Authors
- Kullmann, F., Strissel, P. L., Strick, R., Stoehr, R., Eckstein, M., Bertz, S., Wullich, B., Sikic, D., Wach, S., Taubert, H., Olbert, P., Heers, H., Lara, M. F., Macias, M. L., Matas-Rico, E., Lozano, M. J., Prieto, D., Hierro, I., van Doeveren, T., Bieche, I., Masliah-Planchon, J., Beaurepere, R., Boormans, J. L., Allory, Y., Herrera-Imbroda, B., Hartmann, A., & Weyerer, V.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Brixsana Private Clinic (IT)
- Universitätsklinikum Gießen und Marburg (DE)
- Department of Urology, Virgen de la Victoria University Hospital Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
- Genitourinary Cancer Translational Research Group, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
- Instituto de Investigación Biomédica de Málaga (ES)
- Department of Pathology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain
- Department of Pathology, Unidad de Gestión Clínica de Patología, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Málaga, Spain
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Department of Urology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands
- Department of Genetics, Institut Curie, PSL Research University, Paris, France
- Université Paris Sciences et Lettres (FR)
- Erasmus MC (NL)
- Department of Pathology, René Huguenin Curie Institute, Saint Cloud, Paris, France
- Corresponding author
- Weyerer, Veronika
- ORCID
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2021-09-28
- Volume
- 76
- Issue
- 2
- Pages
- 126-132
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- PMC
- PMC9887356
- OpenAlex
- W3204543246
- Cited by
- 20
- References
- 34
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 3 · 2022: 5
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Clinical Pathology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by-nc)
- OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by-nc)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (cc-by)
- Funders
- Interdisciplinary Center for Clinical Research (IZKF) at the University Hospital of the Friedrich-Alexander University Erlangen-Nürnberg
- ERA-NET TRANSCAN
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- upper tract urothelial carcinoma, microsatellite instability, mismatch repair proteins, Lynch syndrome, concordance
- MeSH terms
- Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Colorectal Neoplasms, Hereditary Nonpolyposis, Humans, Colorectal Neoplasms, Microsatellite Repeats, Microsatellite Instability, DNA Mismatch Repair
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.